Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Impact of Proton Beam Irradiation of an Anatomical Subsegment of the Liver for Hepatocellular Carcinoma.

Hojo H, Parshuram RV, Nakamura N, Arahira S, Akita T, Mitsunaga S, Nakamura M, Motegi A, Kageyama SI, Zenda S, Okumura M, Ikeda M, Akimoto T.

Pract Radiat Oncol. 2019 Oct 1. pii: S1879-8500(19)30276-0. doi: 10.1016/j.prro.2019.09.012. [Epub ahead of print]

PMID:
31585204
2.

Frequency and predictors of detecting early locoregional recurrence/disease progression of oral squamous cell carcinoma with high-risk factors on imaging tests before postoperative adjuvant radiotherapy.

Kibe Y, Nakamura N, Kuno H, Hiyama T, Hayashi R, Zenda S, Motegi A, Hojo H, Nakamura M, Ariji T, Oyoshi H, Akimoto T.

Int J Clin Oncol. 2019 Oct;24(10):1182-1189. doi: 10.1007/s10147-019-01479-x. Epub 2019 Jul 9.

PMID:
31289957
3.

Hypofractionated proton beam therapy for centrally located lung cancer.

Nakamura N, Hotta K, Zenda S, Baba H, Kito S, Akita T, Motegi A, Hojo H, Nakamura M, Parshuram RV, Okumura M, Akimoto T.

J Med Imaging Radiat Oncol. 2019 Aug;63(4):552-556. doi: 10.1111/1754-9485.12901. Epub 2019 May 30.

PMID:
31145553
4.

Norfloxacin, a Fluoroquinolone Antibiotic, Inhibits Langerhans Cell-Mediated Th1 and Th2 Cell Development.

Matsui K, Kashima A, Motegi A.

J Pharm Pharm Sci. 2019 Apr 11;22(1):122-130. doi: 10.18433/jpps30335.

5.

Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.

Nakamura M, Kageyama SI, Niho S, Okumura M, Hojo H, Motegi A, Nakamura N, Zenda S, Yoh K, Goto K, Akimoto T.

Clin Lung Cancer. 2019 May;20(3):e256-e264. doi: 10.1016/j.cllc.2019.02.021. Epub 2019 Mar 4.

6.

Aberrations in DNA repair pathways in cancer and therapeutic significances.

Motegi A, Masutani M, Yoshioka KI, Bessho T.

Semin Cancer Biol. 2019 Oct;58:29-46. doi: 10.1016/j.semcancer.2019.02.005. Epub 2019 Mar 25. Review.

PMID:
30922960
7.

Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.

Okano S, Enokida T, Onoe T, Ota Y, Motegi A, Zenda S, Akimoto T, Tahara M.

Int J Clin Oncol. 2019 Jul;24(7):789-797. doi: 10.1007/s10147-019-01418-w. Epub 2019 Feb 22.

PMID:
30796560
8.

Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak.

Hojo H, Dohmae T, Hotta K, Kageyama SI, Baba H, Kohno R, Motegi A, Tsuchihara K, Akimoto T.

Acta Oncol. 2019 Apr;58(4):475-482. doi: 10.1080/0284186X.2018.1555373. Epub 2019 Jan 11.

PMID:
30632869
9.

Usefulness of hybrid deformable image registration algorithms in prostate radiation therapy.

Motegi K, Tachibana H, Motegi A, Hotta K, Baba H, Akimoto T.

J Appl Clin Med Phys. 2019 Jan;20(1):229-236. doi: 10.1002/acm2.12515. Epub 2018 Dec 27.

10.

Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer.

Nakamura M, Onozawa M, Motegi A, Hojo H, Zenda S, Nakamura N, Udagawa H, Kirita K, Matsumoto S, Umemura S, Yoh K, Niho S, Goto K, Akimoto T.

J Radiat Res. 2018 Nov 1;59(6):767-773. doi: 10.1093/jrr/rry066.

11.

Correction: Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.

Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T.

Oncotarget. 2018 May 4;9(34):23844. doi: 10.18632/oncotarget.25378. eCollection 2018 May 4.

12.

Late radiological changes after passive scattering proton beam therapy for Stage I lung cancer.

Nakamura N, Hojo H, Inoue K, Hotta K, Zenda S, Baba H, Onozawa M, Motegi A, Nakamura M, Kibe Y, Akimoto T.

J Radiat Res. 2018 Jul 1;59(4):456-461. doi: 10.1093/jrr/rry028.

13.

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.

Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T.

Oncotarget. 2018 Apr 10;9(27):19368-19378. doi: 10.18632/oncotarget.25053. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 May 4;9(34):23844.

14.

Palliative radiotherapy for breast cancer patients with skin invasion: a multi-institutional prospective observational study.

Nakamura N, Kawamori J, Takahashi O, Shikama N, Sekiguchi K, Takahashi T, Kato S, Ogita M, Motegi A, Akimoto T.

Jpn J Clin Oncol. 2018 Jun 1;48(6):555-558. doi: 10.1093/jjco/hyy054.

PMID:
29684149
15.

Author Correction: Phosphorylated HBO1 at UV irradiated sites is essential for nucleotide excision repair.

Niida H, Matsunuma R, Horiguchi R, Uchida C, Nakazawa Y, Motegi A, Nishimoto K, Sakai S, Ohhata T, Kitagawa K, Moriwaki S, Nishitani H, Ui A, Ogi T, Kitagawa M.

Nat Commun. 2018 Apr 20;9:16214. doi: 10.1038/ncomms16214.

16.

Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma.

Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K, Moriya S, Tachibana H, Nakamura N, Kojima T, Akimoto T.

Radiat Oncol. 2018 Feb 9;13(1):23. doi: 10.1186/s13014-018-0966-5.

17.

PARI Regulates Stalled Replication Fork Processing To Maintain Genome Stability upon Replication Stress in Mice.

Mochizuki AL, Katanaya A, Hayashi E, Hosokawa M, Moribe E, Motegi A, Ishiai M, Takata M, Kondoh G, Watanabe H, Nakatsuji N, Chuma S.

Mol Cell Biol. 2017 Nov 13;37(23). pii: e00117-17. doi: 10.1128/MCB.00117-17. Print 2017 Dec 1.

18.

Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.

Kumabe A, Zenda S, Motegi A, Onozawa M, Nakamura N, Kojima T, Daiko H, Shigematsu N, Akimoto T.

Anticancer Res. 2017 Sep;37(9):5039-5044.

PMID:
28870931
19.

The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.

Hashimoto Y, Motegi A, Akimoto T, Mitsuhashi N, Iizuka J, Tanabe K, Ishii Y, Kono S, Izumi S, Karasawa K.

Int J Clin Oncol. 2018 Feb;23(1):165-172. doi: 10.1007/s10147-017-1175-1. Epub 2017 Jul 31.

PMID:
28758177
20.

Phosphorylated HBO1 at UV irradiated sites is essential for nucleotide excision repair.

Niida H, Matsunuma R, Horiguchi R, Uchida C, Nakazawa Y, Motegi A, Nishimoto K, Sakai S, Ohhata T, Kitagawa K, Moriwaki S, Nishitani H, Ui A, Ogi T, Kitagawa M.

Nat Commun. 2017 Jul 18;8:16102. doi: 10.1038/ncomms16102. Erratum in: Nat Commun. 2018 Apr 20;9:16214.

21.

Difference in the relative biological effectiveness and DNA damage repair processes in response to proton beam therapy according to the positions of the spread out Bragg peak.

Hojo H, Dohmae T, Hotta K, Kohno R, Motegi A, Yagishita A, Makinoshima H, Tsuchihara K, Akimoto T.

Radiat Oncol. 2017 Jul 3;12(1):111. doi: 10.1186/s13014-017-0849-1.

22.

Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.

Yamazaki T, Tahara M, Enokida T, Wakasugi T, Arahira S, Zenda S, Motegi A, Akimoto T, Yoshisue K.

Jpn J Clin Oncol. 2017 May 1;47(5):407-412. doi: 10.1093/jjco/hyx006.

PMID:
28159957
23.

Proton beam therapy for olfactory neuroblastoma.

Nakamura N, Zenda S, Tahara M, Okano S, Hayashi R, Hojo H, Hotta K, Kito S, Motegi A, Arahira S, Tachibana H, Akimoto T.

Radiother Oncol. 2017 Mar;122(3):368-372. doi: 10.1016/j.radonc.2016.12.020. Epub 2017 Jan 3.

PMID:
28062086
24.

Patterns of failure after postoperative intensity-modulated radiotherapy for locally advanced and recurrent head and neck cancer.

Ooishi M, Motegi A, Kawashima M, Arahira S, Zenda S, Nakamura N, Ariji T, Tokumaru S, Sakuraba M, Tahara M, Hayashi R, Akimoto T.

Jpn J Clin Oncol. 2016 Oct;46(10):919-927. Epub 2016 Aug 10.

PMID:
27511989
25.

Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced non-small cell lung cancer.

Wu CT, Motegi A, Motegi K, Hotta K, Kohno R, Tachibana H, Kumagai M, Nakamura N, Hojo H, Niho S, Goto K, Akimoto T.

Jpn J Clin Oncol. 2016 Aug 10. [Epub ahead of print]

PMID:
27511988
26.

Post-mastectomy radiation therapy without usage of a bolus may be a reasonable option.

Nakamura N, Arahira S, Zenda S, Yoneyama K, Mukai H, Onozawa M, Toshima M, Motegi A, Hirano Y, Hojo H, Kibe Y, Akimoto T.

J Radiat Res. 2017 Jan;58(1):66-70. doi: 10.1093/jrr/rrw055. Epub 2016 Jul 15.

27.

Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation.

Yamazaki T, Enokida T, Wakasugi T, Zenda S, Motegi A, Arahira S, Akimoto T, Tahara M.

Jpn J Clin Oncol. 2016 Sep;46(9):825-31. doi: 10.1093/jjco/hyw079. Epub 2016 Jun 17.

PMID:
27317736
28.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non-Small Cell Lung Cancer.

Zenke Y, Umemura S, Motegi A, Furukawa K, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Akimoto T, Goto K.

J Thorac Oncol. 2016 Jul;11(7):1181-3. doi: 10.1016/j.jtho.2016.04.011. Epub 2016 Apr 22. No abstract available.

29.

Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma.

Motegi A, Fujii S, Zenda S, Arahira S, Tahara M, Hayashi R, Akimoto T.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):461-8. doi: 10.1016/j.ijrobp.2015.11.019. Epub 2015 Nov 18.

PMID:
26867875
30.

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.

Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M.

Oncotarget. 2016 Feb 16;7(7):7701-14. doi: 10.18632/oncotarget.6715.

31.

Parallel Post-Polyketide Synthase Modification Mechanism Involved in FD-891 Biosynthesis in Streptomyces graminofaciens A-8890.

Kudo F, Kawamura K, Furuya T, Yamanishi H, Motegi A, Komatsubara A, Numakura M, Miyanaga A, Eguchi T.

Chembiochem. 2016 Feb 2;17(3):233-8. doi: 10.1002/cbic.201500533. Epub 2016 Jan 8.

PMID:
26630077
32.

Incidence and severity of adverse events associated with re-irradiation for spine or pelvic bone metastases.

Hirano Y, Nakamura N, Zenda S, Hojo H, Motegi A, Arahira S, Toshima M, Onozawa M, Akimoto T.

Int J Clin Oncol. 2016 Jun;21(3):609-14. doi: 10.1007/s10147-015-0930-4. Epub 2015 Nov 27.

PMID:
26614088
33.

Neuropathic Pain Features in Patients with Bone Metastases.

Nakamura N, Takahashi O, Zenda S, Kawamori J, Ogita M, Onozawa M, Arahira S, Toshima M, Motegi A, Hirano Y, Hojo H, Akimoto T.

Clin Oncol (R Coll Radiol). 2016 Mar;28(3):204-8. doi: 10.1016/j.clon.2015.10.007. Epub 2015 Nov 1.

PMID:
26537667
34.

Third Report on Chicken Genes and Chromosomes 2015.

Schmid M, Smith J, Burt DW, Aken BL, Antin PB, Archibald AL, Ashwell C, Blackshear PJ, Boschiero C, Brown CT, Burgess SC, Cheng HH, Chow W, Coble DJ, Cooksey A, Crooijmans RP, Damas J, Davis RV, de Koning DJ, Delany ME, Derrien T, Desta TT, Dunn IC, Dunn M, Ellegren H, Eöry L, Erb I, Farré M, Fasold M, Fleming D, Flicek P, Fowler KE, Frésard L, Froman DP, Garceau V, Gardner PP, Gheyas AA, Griffin DK, Groenen MA, Haaf T, Hanotte O, Hart A, Häsler J, Hedges SB, Hertel J, Howe K, Hubbard A, Hume DA, Kaiser P, Kedra D, Kemp SJ, Klopp C, Kniel KE, Kuo R, Lagarrigue S, Lamont SJ, Larkin DM, Lawal RA, Markland SM, McCarthy F, McCormack HA, McPherson MC, Motegi A, Muljo SA, Münsterberg A, Nag R, Nanda I, Neuberger M, Nitsche A, Notredame C, Noyes H, O'Connor R, O'Hare EA, Oler AJ, Ommeh SC, Pais H, Persia M, Pitel F, Preeyanon L, Prieto Barja P, Pritchett EM, Rhoads DD, Robinson CM, Romanov MN, Rothschild M, Roux PF, Schmidt CJ, Schneider AS, Schwartz MG, Searle SM, Skinner MA, Smith CA, Stadler PF, Steeves TE, Steinlein C, Sun L, Takata M, Ulitsky I, Wang Q, Wang Y, Warren WC, Wood JM, Wragg D, Zhou H.

Cytogenet Genome Res. 2015;145(2):78-179. doi: 10.1159/000430927. Epub 2015 Jul 14. No abstract available.

35.

[Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction].

Niho S, Motegi A, Akimoto T.

Gan To Kagaku Ryoho. 2015 Feb;42(2):144-7. Japanese.

PMID:
25743132
36.

DeCoP, a Dermatitis Control Program using a moderately absorbent surgical pad for head and neck cancer patients receiving radiotherapy: a retrospective analysis.

Zenda S, Ishi S, Akimoto T, Arahira S, Motegi A, Tahara M, Hayashi R, Asanuma C.

Jpn J Clin Oncol. 2015 May;45(5):433-8. doi: 10.1093/jjco/hyv010. Epub 2015 Feb 11.

PMID:
25673153
37.

Rad18 and Rnf8 facilitate homologous recombination by two distinct mechanisms, promoting Rad51 focus formation and suppressing the toxic effect of nonhomologous end joining.

Kobayashi S, Kasaishi Y, Nakada S, Takagi T, Era S, Motegi A, Chiu RK, Takeda S, Hirota K.

Oncogene. 2015 Aug 13;34(33):4403-11. doi: 10.1038/onc.2014.371. Epub 2014 Nov 24.

PMID:
25417706
38.

Accelerated radiotherapy for T1 to T2 glottic cancer.

Motegi A, Kawashima M, Arahira S, Zenda S, Toshima M, Onozawa M, Hayashi R, Akimoto T.

Head Neck. 2015 Apr;37(4):579-84. doi: 10.1002/hed.23641. Epub 2014 Apr 10.

PMID:
24677592
39.

Multiple genetic manipulations of DT40 cell line.

Motegi A, Takata M.

Methods Mol Biol. 2014;1114:25-35. doi: 10.1007/978-1-62703-761-7_3.

PMID:
24557895
40.

Radiation-induced dimer formation of EGFR: implications for the radiosensitizing effect of cetuximab.

Kiyozuka M, Akimoto T, Fukutome M, Motegi A, Mitsuhashi N.

Anticancer Res. 2013 Oct;33(10):4337-46.

PMID:
24123001
41.

Locoregional control after intensity-modulated radiotherapy for nasopharyngeal carcinoma with an anatomy-based target definition.

Kawashima M, Ariji T, Kameoka S, Ueda T, Kohno R, Nishio T, Arahira S, Motegi A, Zenda S, Akimoto T, Tahara M, Hayashi R.

Jpn J Clin Oncol. 2013 Dec;43(12):1218-25. doi: 10.1093/jjco/hyt144. Epub 2013 Sep 26.

PMID:
24072854
42.

The SUMO protease SENP1 is required for cohesion maintenance and mitotic arrest following spindle poison treatment.

Era S, Abe T, Arakawa H, Kobayashi S, Szakal B, Yoshikawa Y, Motegi A, Takeda S, Branzei D.

Biochem Biophys Res Commun. 2012 Sep 28;426(3):310-6. doi: 10.1016/j.bbrc.2012.08.066. Epub 2012 Aug 27.

PMID:
22943854
43.

Dropped head syndrome induced by chemoradiotherapy for nasopharyngeal carcinoma: a case report.

Hashimoto Y, Maebayashi K, Izumi S, Motegi A, Mitsuhashi N.

Jpn J Clin Oncol. 2012 Nov;42(11):1091-3. doi: 10.1093/jjco/hys135. Epub 2012 Aug 22.

PMID:
22914321
44.

Dpb11/TopBP1 plays distinct roles in DNA replication, checkpoint response and homologous recombination.

Germann SM, Oestergaard VH, Haas C, Salis P, Motegi A, Lisby M.

DNA Repair (Amst). 2011 Feb 7;10(2):210-24. doi: 10.1016/j.dnarep.2010.11.001. Epub 2010 Dec 3.

PMID:
21130053
45.

Simultaneous disruption of two DNA polymerases, Polη and Polζ, in Avian DT40 cells unmasks the role of Polη in cellular response to various DNA lesions.

Hirota K, Sonoda E, Kawamoto T, Motegi A, Masutani C, Hanaoka F, Szüts D, Iwai S, Sale JE, Lehmann A, Takeda S.

PLoS Genet. 2010 Oct 7;6(10). pii: e1001151. doi: 10.1371/journal.pgen.1001151.

46.

Cloning and characterization of the biosynthetic gene cluster of 16-membered macrolide antibiotic FD-891: involvement of a dual functional cytochrome P450 monooxygenase catalyzing epoxidation and hydroxylation.

Kudo F, Motegi A, Mizoue K, Eguchi T.

Chembiochem. 2010 Jul 26;11(11):1574-82. doi: 10.1002/cbic.201000214. Erratum in: Chembiochem. 2010 Sep 3;11(13):1798.

PMID:
20589823
47.

[Maintenance of genome stability though Ubc13-dependent ubiquitination].

Motegi A.

Seikagaku. 2009 Jul;81(7):601-5. Review. Japanese. No abstract available.

PMID:
19697864
48.

The cytotoxic macrolide FD-891 induces caspase-8-dependent mitochondrial release of cytochrome c and subsequent apoptosis in human leukemia Jurkat cells.

Inaba S, Eguchi T, Motegi A, Mizoue K, Usui T, Nagai K, Kataoka T.

J Antibiot (Tokyo). 2009 Sep;62(9):507-12. doi: 10.1038/ja.2009.62. Epub 2009 Jul 10.

PMID:
19590527
49.

[Function of homologous recombination-mediated DNA repair].

Motegi A, Takeda S.

Tanpakushitsu Kakusan Koso. 2009 Mar;54(4 Suppl):450-8. Review. Japanese. No abstract available.

PMID:
21089491
50.

The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.

Motegi A, Murakawa Y, Takeda S.

Cancer Lett. 2009 Sep 28;283(1):1-9. doi: 10.1016/j.canlet.2008.12.030. Epub 2009 Feb 6. Review.

PMID:
19201084

Supplemental Content

Loading ...
Support Center